Abbott obtains fda clearance for first test that simultaneously detects four common sexually transmitted infections (stis) as cases are on the rise

Abbott's multiplex test runs on its most advanced molecular pcr platform, the alinity™ m system, which provides fast results in high volumes – detecting four infections simultaneously test provides a critically important tool as people return to regular sti testing; a pause in testing during the pandemic contributed to an increase of sti cases 1,2 pandemic has shown value of at-home testing and sample collection, and abbott plans to bring that convenience and discretion to additional areas in the future, including for stis abbott park, ill., may 4, 2022 /prnewswire/ -- abbott (nyse: abt) announced today it has received fda clearance for its alinity™ m sti assay.
ABT Ratings Summary
ABT Quant Ranking